|
|
Article: Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia.
- Article from:
- PR Newswire
- Article date:
- June 12, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BETHESDA and GAITHERSBURG, Md., June 12 /PRNewswire-FirstCall/ -- Micromet, Inc. and MedImmune announced today that the first patient has started treatment in a multi-center, phase 2 trial conducted in Germany investigating BiTE(R) antibody blinatumomab (MT103/MEDI-538) in patients with adult acute lymphoblastic leukemia (ALL). Blinatumomab is a T cell engaging antibody targeting the CD19 antigen, which is only expressed on B cells. The clinical development program for blinatumomab was expanded to include ALL as an additional indication after data from an ongoing phase 1 clinical trial showed potent single-agent activity of the BiTE antibody in patients with late-stage ...